Page 166 - TD-3-4

Tumor Discovery CK2 deregulation in non-small-cell lung cancer

Clinical Research Ethics Review in Traditional Chinese 5. Borgo C, D’Amore C, Cesaro L, et al. How can a traffic light
Medicine, and the International Ethical Guidelines for properly work if it is always green? The paradox of CK 2
Biomedical Research Involving Human Subjects. This signaling. Crit Rev Biochem Mol Biol. 2021;56(4):321-359.
project, titled “Research on Novel Peptide Drugs Targeting doi: 10.1080/10409238.2021.1908951
CK2-Mediated Phosphorylation for the Treatment of 6. Salvi M, Borgo C, Pinna LA, Ruzzene M. Targeting CK in
2
Non-Small-Cell Lung Cancer (NSCLC)” was reviewed and cancer: A valuable strategy or a waste of time? Cell Death
approved by the Nanhua University Affiliated First Hospital Discov. 2021;7(1):325.
Medical Ethics Review Committee. Review information doi: 10.1038/s41420-021-00717-4
is as follows: Review Batch Number: 2021LL0115001;
Meeting Date: January 15, 2021. Reviewed Materials: 7. Wells CI, Drewry DH, Pickett JE, et al. Development of a
Research Plan Version: YJFA20210114; Informed Consent potent and selective chemical probe for the pleiotropic
Form Version: ZQTY20210114. Signature by Medical kinase CK . Cell Chem Biol. 2021;28(4):546-558.e10.
2
Ethics Committee of Nanhua University Affiliated First doi: 10.1016/j.chembiol.2020.12.013
Hospital Issuance Date: January 15, 2021. 8. Licciardello MP, Workman P. A New chemical probe
challenges the broad cancer essentiality of CK . Trends
Consent for publication Pharmacol Sci. 2021;42(5):313-315. 2
Written informed consent forms were obtained for the doi: 10.1016/j.tips.2021.02.002
participation and subsequent publication of human data 9. Cozza G. The development of CK inhibitors: From
2
masking or concealing any identifying information of the traditional pharmacology to in silico rational drug design.
patients. Pharmaceuticals (Basel). 2017;10(1):26.
Availability of data doi: 10.3390/ph10010026
The original contributions presented in the study are 10. Bancet A, Frem R, Jeanneret F, et al. AB668, a novel highly
selective protein kinase CK inhibitor with a distinct
2
included in the article/supplementary material; further anti-tumor mechanism as compared to CX-4945 and
inquiries can be directed to the corresponding author/s. SGC-CK2-1. bioRxiv [Preprint]. 2022.
Further disclosure doi: 10.1101/2022.12.16.520736
Part of the analysis/data has been uploaded to or deposited 11. Solares AM, Santana A, Baladrón I, et al. Safety and
preliminary efficacy data of a novel casein kinase 2 (CK )
as preliminary findings in a preprint server BioRxiv peptide inhibitor administered intralesionally at four dose
2
doi: https://doi.org/10.1101/2023.08.04.551954. levels in patients with cervical malignancies. BMC Cancer.
References 2009;9:146.
doi: 10.1186/1471-2407-9-146
1. Ruzzene M, Pinna LA. Addiction to protein kinase CK2:
A common denominator of diverse cancer cells? Biochim 12. Pierre F, Chua PC, O’Brien SE, et al. Discovery and SAR
[2 6
Biophys Acta. 2010;1804(3):499-504. of 5-(3-chlorophenylamino)benzo[c] , naphthyridine-8-
carboxylic acid (CX-4945), the first clinical stage inhibitor of
doi: 10.1016/j.bbapap.2009.07.018 protein kinase CK2 for the treatment of cancer. J Med Chem.
2. Borgo C, Franchin C, Cesaro L, et al. A Proteomics analysis 2011;54(2):635-654.
of CK2β (-/-) C C Cells provides novel insights into the doi: 10.1021/jm101251q
12
2
biological functions of the non-catalytic β subunit. FEBS J.
2019;286(8):1561-1575. 13. Strum SW, Gyenis L, Litchfield DW. CSNK2 in cancer:
Pathophysiology and translational applications. Br J Cancer.
doi: 10.1111/febs.14799 2022;126(7):994-1003.
3. Roffey SE, Litchfield DW. CK regulation: Perspectives in doi: 10.1038/s41416-021-01616-2
2
2021. Biomedicines. 2021;9(10):1361.
14. Cerami E, Gao J, Dogrusoz U, et al. The CBio cancer genomics
doi: 10.3390/biomedicines9101361 portal: An open platform for exploring multidimensional
4. Trembley JH, Kren BT, Afzal M, Scaria GA, Klein MA, cancer genomics data. Cancer Discov. 2012;2(5):401-404.
Ahmed K. Protein kinase CK - diverse roles in cancer doi: 10.1158/2159-8290.CD-12-0095
2
cell biology and therapeutic promise. Mol Cell Biochem. 15. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis
2023;478(4):899-926.
of complex cancer genomics and clinical profiles using the
doi: 10.1007/s11010-022-04558-2 CBioPortal. Sci Signal. 2013;6(269):pl1.

Volume 3 Issue 4 (2024) 12 doi: 10.36922/td.4571